This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

BENJAMIN MILDER, M.D.

Arch Ophthalmol. 1961;66(1):70-72.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The importance of cycloplegia in refraction is attested to by the continuing search for the ideal cycloplegic drug. This ideal drug should provide (1) maximum relaxation of accommodation; (2) satisfactory mydriasis; (3) rapid onset of action and rapid attainment of maximum effect; (4) short duration and rapid recovery; (5) consistency in its effectiveness; (6) freedom from toxicity, irritation, or sensitivity.

For many decades, homatropine was the drug of choice for cycloplegia in refraction. Several newer drugs have far surpassed homatropine in all of the above qualifications except one. Unfortunately that one is the first and most important of all—maximum cycloplegic effect¹! The search goes on.

Recently, tropicamide * has claimed the attention of investigators and clinicians. Tropicamide is a parasympatholytic drug (N-ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide). It was introduced on the European continent, and has been reported on recently in the American literature.^2,3 Merrill et al.,² in a study of 262 patients . . . [Full Text PDF of this Article]

Author Affiliations
St. Louis

From the Department of Ophthalmology and the Oscar Johnson Institute, Washington University School of Medicine.

Footnotes
Submitted for publication Dec. 28, 1960.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?